A historical cohort study on glycemic-control and cancer-risk among patients with diabetes. (December 2018)

• Record Type: Journal Article
• Authors: Dankner, R.; Boker, L. Keinan; Boffetta, P.; Balicer, R.D.; Murad, H.; Berlin, A.; Olmer, L.; Agai, N.; Freedman, LS
• Is Part Of: Cancer epidemiology. Volume 57(2018:Dec.)
• Page Start: 104
• Page End: 109
• Publication Date: 2018-12
• Subjects: Glycemic-control -- HbA1c -- Blood glucose control -- Risk -- Missing data -- Multiple imputation -- Cohort -- Cancer; Cancer -- Epidemiology -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Carcinogenesis -- Periodicals; 616.994005
• DOI: 10.1016/j.canep.2018.10.010
• Languages: English
• ISSNs: 1877-7821

Abstract

Highlights: Among 440, 000 diabetic patients with over 26, 000 cancer events, glycemic control had little or no association with risk of of most selected cancer. Poorer glycemic control had a strong positive association with pancreatic cancer and a moderate negative association with prostate cancer. Hyperglycemia does not appear to provide the main explanation for the generally raised cancer risk among people with diabetes. Abstract: Aims: This population-based historical cohort study examined whether poor glycemic-control (i.e., high glucose and HbA1c blood levels) in patients with diabetes is associated with cancer-risk. Methods: From a large healthcare database, patients aged 21–89 years, diagnosed with diabetes before January 2002 (prevalent) or during 2002–2010 (incident), were followed for cancer during 2004–2012 (excluding cancers diagnosed within the first 2 years since diabetes diagnosis). Risks of selected cancers (all-sites, colon, breast, lung, prostate, pancreas and liver) were estimated according to glycemic-control in a Cox regression model with time-dependent covariates, adjusted for age, sex, ethnic origin, socioeconomic status, smoking and parity. Missing glucose or HbA1c values were imputed. Results: Among 440, 000 patients included in our analysis, cancer was detected more than 2 years after diabetes diagnosis in 26, 887 patients (6%) during the follow-up period. Associations of poor glycemic-control with all-sites cancer and most specific cancers were either null or only weak (hazard ratios (HRs) for a 1% HbA1c or a 30 mg/dl glucose increase between 0.94 and 1.09). Exceptions were pancreatic cancer, for which there was a strong positive association (HRs: 1.26–1.51), and prostate cancer, for which there was a moderate negative association (HRs: 0.85–0.96). Conclusion: Overall, poor glycemic-control appears to be only weakly associated with cancer-risk, if at all. A substantial part of the positive association with pancreatic cancer is attributable to reverse causation, with the cancer causing poorer glycemic-control prior to its diagnosis. The negative association with prostate cancer may be related to lower PSA levels in those with poor control.